JY HEALTHCARE GROUP SDN BHD (1185177-T)

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com

Ref No : MLJC/JYHCG/GHBI/NANOROBOT/2026-08/21/15.00
Date : 21 August 2026

GLOBAL HEALTHCARE & BIOMEDICAL INTELLIGENCE

MLJC EXCLUSIVE | BIOMEDICAL INNOVATION INTELLIGENCE

WHEN MEDICINE LEARNS TO FIND ITS WAY

Injectable Chemotactic Nanorobots and a New Frontier in Precision Cancer Therapy

Nanorobotics | Nanomedicine | Precision Oncology | Drug Delivery | Biomedical Engineering | Translational Medicine

EXECUTIVE SUMMARY

In recent years, the idea of **"nanorobots treating cancer"** has increasingly entered public discussion.

Among the emerging research attracting international attention is work led by **Professor Jianguo Guan and his team at Wuhan University of Technology**, who have developed an injectable nanorobot system designed to actively navigate the tumour microenvironment and improve the delivery of therapeutic agents.

The research, entitled:

"Bienzyme-powered nanorobots with ultrasensitive chemotaxis for precision cancer therapy"

was published in *National Science Review* and provides preclinical evidence for a new approach to tumour-targeted drug delivery.

JY HEALTHCARE GROUP SDN BHD (1185177-T)

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com

The significance of this work is not that:

“A single injection can already cure cancer.”

It cannot yet be described that way.

The more important scientific question is:

Can a drug-delivery system do more than simply travel with the bloodstream — can it sense its biological environment and use that information to move towards a tumour?

That is the question this research begins to address.

I. FIRST, WHAT EXACTLY IS A “NANOROBOT”?

The term **nanorobot** can easily create an image of a miniature mechanical robot equipped with a computer, battery and robotic arms.

That is not what is being described here.

The system developed by the research team is better understood as an **engineered functional nanomaterial capable of chemically driven motion and chemotactic behaviour**.

The researchers constructed a Janus nanorobot based on gold nanoparticles and incorporated two functional enzymes:

Urease

Provides chemical propulsion.

Catalase

Responds to hydrogen-peroxide-related chemical gradients and contributes to directional behaviour.

JY HEALTHCARE GROUP SDN BHD (1185177-T)

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com

The result is a system capable of combining:

PROPULSION + ORIENTATION

In other words:

movement

combined with

directional guidance.

This is a much more scientifically accurate description than imagining a conventional mechanical robot operating inside the human body.



JY HEALTHCARE GROUP SDN BHD (1185177-T)

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com

II. WHAT PROBLEM IS THE RESEARCH TRYING TO SOLVE?

Modern nanomedicine has spent decades developing increasingly sophisticated drug-delivery systems.

Liposomal formulations, polymeric nanoparticles, mesoporous materials and other nanoscale carriers have all attempted to address the same fundamental problem:

How can more therapeutic payload actually reach the tumour, penetrate the tumour and enter the target cells?

The challenge is particularly significant in solid tumours.

A therapeutic agent may be administered successfully, yet still face:

limited tumour accumulation
↓
poor penetration
↓
biological barriers
↓
limited cellular internalisation
↓
insufficient therapeutic exposure at the target site

The Wuhan University of Technology study therefore explores a different concept.

Conventional approach
Injection
↓
Blood circulation
↓
Passive transport
↓
Tumour accumulation
↓
Drug release

JY HEALTHCARE GROUP SDN BHD (1185177-T)

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com

Emerging approach

Injection
↓
Blood circulation
↓
Chemical propulsion
↓
Chemotactic navigation
↓
Tumour targeting
↓
Deep tissue penetration
↓
Cellular internalisation
↓
Therapeutic delivery

This transition from **passive delivery to active navigation** is arguably the most important aspect of the research.

JY HEALTHCARE GROUP SDN BHD (1185177-T)

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com



JY HEALTHCARE GROUP SDN BHD (1185177-T)

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com

III. THE BODY'S CHEMICAL ENVIRONMENT AS A NAVIGATION SYSTEM

One of the most interesting elements of the research is its use of the tumour microenvironment as a form of biological guidance.

The researchers designed the nanorobot to respond to chemical gradients associated with the tumour microenvironment.

In particular, hydrogen peroxide-related gradients provide directional information, while urea serves as a chemical substrate for urease-driven propulsion.

The system therefore combines two distinct functions:

PROPULSION

Using urease to generate movement.

ORIENTATION

Using catalase-mediated chemotactic behaviour to influence direction.

This is an elegant engineering principle:

USE THE BIOLOGICAL ENVIRONMENT TO HELP GUIDE THE THERAPEUTIC SYSTEM.

The body is no longer simply the place where the drug is delivered.

Its own biochemical landscape becomes part of the navigation mechanism.

IV. WHAT DID THE PRECLINICAL DATA SHOW?

This is where scientific discipline becomes essential.

The current evidence is based on:

TUMOUR-BEARING MOUSE MODELS

JY HEALTHCARE GROUP SDN BHD (1185177-T)

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com

It is **not human clinical evidence**.

Within the experimental systems reported by the researchers, the nanorobot demonstrated substantial improvements compared with passive delivery controls.

The published study reported approximately:

209-fold improvement

in tumour-targeting delivery efficiency.

More than 10-fold improvement

in tumour penetration depth.

Approximately 1,970-fold improvement

in cellular internalisation efficiency.

The researchers also reported an approximately:

49-fold improvement

in tumour-suppression performance compared with the corresponding passive diffusion system in the experimental model.

These are significant preclinical findings.

But they must remain exactly that:

PRECLINICAL FINDINGS

They should not be presented as human clinical outcomes.

JY HEALTHCARE GROUP SDN BHD (1185177-T)

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com

V. THE 92.7% FIGURE — AND WHY CONTEXT MATTERS

The study also used Ce6-loaded nanorobots in a photodynamic therapy model.

Under the specific experimental conditions reported by the researchers, the system achieved:

92.7% TUMOUR GROWTH INHIBITION

The study also reported that the therapeutic payload could be administered at approximately **1% of the conventional injection dose used in the comparison system**, while retaining substantial antitumour activity in the experimental model.

However, this does **not** mean:

“Cancer patients only need 1% of the normal drug dose.”

Nor does it mean:

“A single injection achieves 92.7% cancer treatment efficacy in humans.”

It means:

Under the specific conditions of the animal experiment, active nanorobot-mediated delivery substantially improved therapeutic efficiency.

This distinction is essential.

JY HEALTHCARE GROUP SDN BHD (1185177-T)

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com



JY HEALTHCARE GROUP SDN BHD (1185177-T)

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com

VI. THE MOST IMPORTANT NUMBER MAY NOT BE 92.7%

A headline naturally gravitates towards:

92.7%

because it is easy to communicate.

But from an MLJC analytical perspective, the more revealing figures may be:

209×

Targeting efficiency

>10×

Tumour penetration

1,970×

Cellular internalisation

49×

Experimental therapeutic improvement versus passive delivery

Together, these figures point towards something much more important than a new "miracle cancer drug".

They suggest a new way of thinking about:

HOW THERAPEUTIC PAYLOADS REACH DISEASE.

The innovation is therefore primarily a:

Drug-Delivery System Innovation

rather than a clinically established new cancer treatment.

JY HEALTHCARE GROUP SDN BHD (1185177-T)

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com

VII. THE NEXT GENERATION OF CANCER THERAPY MAY NOT ONLY REQUIRE BETTER DRUGS

For decades, oncology has focused heavily on developing:

Better drugs.

The next stage may require equal attention to:

Better delivery systems.

Because a powerful therapeutic molecule is only useful if it can:

reach the tumour
↓
penetrate the tumour
↓
reach the relevant cells
↓
release its payload
↓
produce the intended biological response

This creates a new competitive frontier:

BETTER DRUGS

combined with

BETTER DELIVERY SYSTEMS

and eventually:

INTELLIGENT THERAPEUTIC DELIVERY

JY HEALTHCARE GROUP SDN BHD (1185177-T)

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com

VIII. WHY THIS IS MORE THAN A NANOTECHNOLOGY STORY

The research sits at the intersection of multiple disciplines:

Nanotechnology
×
Materials Science
×
Chemical Engineering
×
Biological Engineering
×
Cancer Biology
×
Drug Delivery
×
Precision Medicine

This makes the work particularly interesting from a translational perspective.

It represents:

BIOMEDICAL ENGINEERING IN ACTION

The engineering question is no longer simply:

“Can we create a smaller particle?”

It becomes:

“Can we engineer a therapeutic system that understands and responds to its biological environment?”

That is a much larger scientific proposition.

JY HEALTHCARE GROUP SDN BHD (1185177-T)

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com

IX. THE CRITICAL DISTANCE BETWEEN A PAPER AND A PATIENT

This is where MLJC believes responsible medical intelligence must be different from medical marketing.

The research is promising.

But it remains:

PRECLINICAL

Before such technology could become an accepted human treatment, it would need to pass through multiple stages.

1. Material Safety

Does the system remain biologically safe over the required treatment period?

2. Biocompatibility

How does the human immune system respond?

3. Biodistribution

Where do the nanorobots actually travel throughout the body?

4. Clearance

How are the materials metabolised, degraded or eliminated?

5. Dose Control

Can propulsion, targeting and therapeutic exposure be reliably controlled?

6. Off-Target Effects

Could the system accumulate in healthy organs or tissues?

7. Manufacturing

Can the technology be produced consistently at pharmaceutical quality and scale?

JY HEALTHCARE GROUP SDN BHD (1185177-T)

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com

8. Clinical Evidence

Will the results observed in animal models translate into meaningful benefits for human patients?

Only after these questions are answered can a laboratory innovation move meaningfully towards:

CLINICAL PRACTICE

X. FROM SCIENTIFIC DISCOVERY TO MEDICAL TECHNOLOGY

MLJC sees a broader translational pathway:

Laboratory Discovery
↓
Material Engineering
↓
Preclinical Validation
↓
Toxicology & Safety
↓
Large-Animal Studies
↓
Regulatory Review
↓
Human Clinical Trials
↓
Clinical Validation
↓
Manufacturing & Commercialisation
↓
STANDARD OF CARE

This distinction is important.

A scientific paper represents a discovery.

A successful animal study represents preclinical evidence.

A clinical trial represents human evidence.

Regulatory approval represents a different threshold again.

And widespread clinical adoption requires still another level of evidence.

Science must earn each step.

XI. MLJC STRATEGIC VIEW

The phrase:

"Cancer treatment could one day be as simple as an injection."

is powerful.

But the deeper question is much more interesting:

CAN MEDICINE BECOME NAVIGABLE?

Can therapeutic systems:

sense
↓
navigate
↓
target
↓
penetrate
↓
deliver
↓
respond
?

If this field matures, the nanorobot may ultimately become more than a drug carrier.

JY HEALTHCARE GROUP SDN BHD (1185177-T)

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com

It could potentially become a platform integrating:

Sensing

Navigation

Targeting

Therapeutic delivery

Imaging

and eventually:

Real-time monitoring

The long-term architecture could therefore resemble:

SENSE → NAVIGATE → TARGET → DELIVER → RESPOND

That is where the deeper potential of medical nanorobotics may lie.

JY HEALTHCARE GROUP SDN BHD (1185177-T)

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com



JY HEALTHCARE GROUP SDN BHD (1185177-T)

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com

XII. CHINA'S ROLE IN THE EMERGING FIELD

China's development in nanomedicine and biomedical engineering deserves continued international observation.

The significance is not simply that:

"China has developed a nanorobot."

The larger question is whether China can build a complete translational ecosystem connecting:

Advanced Materials
→
Nanotechnology
→
Biomedical Engineering
→
Preclinical Research
→
Clinical Medicine
→
Regulatory Science
→
Pharmaceutical Manufacturing
→
Global Healthcare Applications

That is ultimately what determines whether a laboratory breakthrough becomes a medical technology.

JY HEALTHCARE GROUP SDN BHD (1185177-T)

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com

XIII. MLJC | JY HCG'S PRINCIPLE OF MEDICAL INTELLIGENCE

MLJC | JY HCG adopts a simple principle:

SEE THE BREAKTHROUGH — BUT ALSO SEE THE BOUNDARY.

We should recognise scientific progress without turning it into mythology.

We should acknowledge promising evidence without presenting it as proven clinical treatment.

We should report the achievement.

But we should also report:

what has been demonstrated;

what has not yet been demonstrated;

and

what must be demonstrated next.

This is particularly important when the subject concerns human life.

XIV. A CONFUCIAN APPROACH TO MEDICAL INNOVATION

There is a traditional principle that remains relevant to modern science:

"知之为知之，不知为不知，是知也。"

To know what is known, and to acknowledge what is not yet known — that is knowledge.

For MLJC | JY HCG, this is more than philosophy.

It is an editorial discipline.

Do not exaggerate what has been achieved.

Do not dismiss what has not yet matured.

Do not confuse possibility with proof.

Do not confuse a laboratory result with a clinical outcome.

And above all:

When science concerns human life, accuracy is itself a form of responsibility.

XV. MLJC FINAL ASSESSMENT

The Wuhan University of Technology study does **not** yet tell us:

"One injection can cure cancer."

But it does demonstrate an important preclinical possibility:

A chemically powered nanorobot can be engineered to respond to tumour-associated chemical gradients and substantially improve targeted drug delivery in animal tumour models.

That is already meaningful.

Not because it is the end of cancer treatment.

But because it opens another route towards solving one of medicine's oldest problems:

HOW DO WE GET THE RIGHT THERAPY TO THE RIGHT PLACE?

The future of oncology may therefore depend not only on discovering:

better medicines,

but also on engineering:

better ways to deliver them.

From:

Passive Delivery

to

Active Navigation

JY HEALTHCARE GROUP SDN BHD (1185177-T)

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com

From:

Drug Carriers

to

Intelligent Therapeutic Systems

From:

Where does the drug go?

to:

Can we engineer where the drug should go?

That is the question worth watching.

JY HEALTHCARE GROUP SDN BHD (1185177-T)

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com

MLJC | JYHCG
全球医疗与生物医学战略情报

MLJC 独家 | 生物医学创新观察

让药物自己寻找方向

可注射趋化纳米机器人：精准肿瘤治疗的一项中国探索

Nanorobotics | Nanomedicine | Precision Oncology | Drug Delivery | Biomedical Engineering

一、引言 | 从“一针”谈起，但不止于“一针”

近年来，关于“纳米机器人治疗癌症”的讨论不断进入公众视野。

其中，一项来自中国武汉理工大学官建国教授团队的研究尤其值得关注。

研究团队开发了一种具有**双酶驱动与趋化能力的 Janus 纳米机器人**，并将其用于肿瘤药物递送研究。

论文：

“Bienzyme-powered nanorobots with ultrasensitive chemotaxis for precision cancer therapy”

发表于 National Science Review，由 Oxford Academic 平台收录，论文于 2025 年 12 月 18 日发表，并于 2026 年正式刊载。

这项研究值得关注，并不是因为“机器人已经可以治愈癌症”。

JY HEALTHCARE GROUP SDN BHD (1185177-T)

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com

恰恰相反。

它的价值在于，它提出了一个更加朴素、却更加重要的问题：

能否让药物递送系统，不再只是被动地随血液流动，而能够利用人体内部的化学环境，主动寻找肿瘤所在的方向？

这可能才是这项研究真正值得国际医学界讨论的地方。



JY HEALTHCARE GROUP SDN BHD (1185177-T)

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com

二、首先要把一个概念说清楚

它不是我们想象中的“微型机器人”

大众语境中的“机器人”，容易让人联想到：

机械手臂、电脑芯片、人工智能、GPS 定位。

但医学纳米机器人目前并不是这样的概念。

此次研究中的纳米机器人，本质上是一种经过工程化设计的**功能纳米颗粒系统**。

研究团队以金纳米颗粒（AuNPs）为基础，在其表面构建具有不同功能的酶系统：

Urease | **脲酶**

负责推动运动；

Catalase | **过氧化氢酶**

负责感知肿瘤微环境中的过氧化氢（H_2O_2）梯度并帮助调整方向。

因此，它更准确的定义应该是：

Chemically propelled, chemotactic nanorobot

即：

化学驱动、具有趋化能力的纳米机器人。

而不是科幻意义上的“微型机械人”。

JY HEALTHCARE GROUP SDN BHD (1185177-T)

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com



JY HEALTHCARE GROUP SDN BHD (1185177-T)

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com

三、这项研究真正解决的是什么问题？

这是理解这篇论文的关键。

现代纳米药物递送已经发展多年。

脂质体、聚合物纳米颗粒、介孔材料、金纳米颗粒等，都在尝试解决同一个问题：

如何让更多治疗药物真正到达肿瘤，而不是在到达之前就被人体其他组织清除或截留？

论文指出，现有纳米颗粒递送系统普遍存在：

肿瘤靶向效率有限

以及：

实体瘤内部穿透能力不足

等问题。

因此，研究团队试图改变一个传统逻辑：

传统方式

注射
↓
血液循环
↓
被动扩散
↓
肿瘤累积
↓
药物释放

而他们探索的是：

新方式
注射
↓
血液循环
↓
化学驱动
↓
感知化学梯度
↓
趋向肿瘤
↓
深入肿瘤组织
↓
细胞内化
↓
递送治疗载荷

这就是这项研究最有价值的地方。

四、人体内部的“化学环境”，可能成为导航系统

研究团队利用了肿瘤微环境中的化学差异。

其中：

H_2O_2浓度梯度

可以作为方向信息。

而：

尿素（urea）

则为脲酶驱动系统提供化学“燃料”。

研究设计实际上将两个功能进行了分工：

脲酶

负责：

Propulsion

推动。

过氧化氢酶

负责：

Orientation

方向调整。

因此形成：

PROPULSION + ORIENTATION

也就是：

推动 + 导向

论文将其类比为汽车：

一个负责提供动力，一个负责控制方向。

这是一个非常直观的工程思想。

五、动物实验告诉了我们什么？

这里必须非常严谨。

目前公开论文的关键体内证据来自：

Tumor-bearing mouse models

即：

荷瘤小鼠模型。

并非人体临床试验。

研究团队报告，在小鼠模型中，这种双酶纳米机器人相比被动对照体系表现出明显提升。

论文报告的数据：

肿瘤靶向递送效率：约提高 209 倍

肿瘤组织穿透深度：超过 10 倍

细胞内化效率：约提高 1,970 倍

当纳米机器人作为抗肿瘤药物载体时，研究报告其肿瘤抑制效果相对于被动对照体系提高约：

49 倍

这些数据均来自研究团队的实验体系，而不是人体临床疗效。

JY HEALTHCARE GROUP SDN BHD (1185177-T)

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com

六、一个更令人关注的数据：92.7%

研究进一步使用载有光敏剂 Ce6 的纳米机器人进行光动力治疗实验。

在特定的小鼠实验条件下，研究报告：

92.7% Tumor Growth Inhibition

即：

92.7%的肿瘤生长抑制率。

同时，研究报告在相应实验中将给药剂量降低至此前递送体系约 1% 的水平。

但这里必须把实验条件一起说明：

这不是说：

“人体只需要 1%的抗癌药物剂量。”

也不是：

“癌症患者使用一针即可达到 92.7%疗效。”

它只代表：

在该研究设计的小鼠模型及特定治疗条件下，纳米机器人显著增强了治疗载荷的递送效率。

这正是科学报道应该保持的分寸。

JY HEALTHCARE GROUP SDN BHD (1185177-T)

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com



JY HEALTHCARE GROUP SDN BHD (1185177-T)

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com

七、真正值得关注的数字，其实不是“92.7%”

如果只是追求传播效果，92.7%非常吸引人。

但从 MLJC 的角度，更重要的是：

209×

靶向递送效率

>10×

肿瘤穿透深度

1,970×

细胞内化效率

49×

相对于被动对照体系的治疗效果提升

这些数据共同说明：

研究的核心并不是制造一个更“神奇”的抗癌药，而是重新设计药物进入肿瘤的路径。

这是一种**递送系统创新**。

而不是一种已经完成临床验证的“新癌症疗法”。

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com

八、MLJC 认为，这项研究真正重要的地方在这里

癌症治疗过去很大程度上是在寻找：

更好的药物。

而未来医学可能同时需要寻找：

更好的药物递送系统。

因为一个药物即使具有很好的生物学作用，如果：

无法到达肿瘤

或者：

无法穿透肿瘤

或者：

无法进入目标细胞

那么它的治疗潜力仍然可能受到限制。

因此，未来的竞争可能从：

BETTER DRUGS

进一步发展到：

BETTER DELIVERY SYSTEMS

甚至：

INTELLIGENT THERAPEUTIC DELIVERY

JY HEALTHCARE GROUP SDN BHD (1185177-T)

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com

九、这项技术为什么具有跨学科意义？

这并不只是纳米材料研究。

它同时涉及：

材料科学
×
纳米技术
×
化学工程
×
生物工程
×
肿瘤生物学
×
药物递送
×
精准医学

因此，它真正代表的是：

BIOMEDICAL ENGINEERING

即：

用工程思想重新解决医学问题。

这也是 MLJC 长期值得关注的一条科技主线：

当材料科学开始理解生物环境，生物环境开始成为工程系统的一部分，医学治疗就可能出现新的技术路径。

JY HEALTHCARE GROUP SDN BHD (1185177-T)

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com

十、但距离人体应用，还有很长的一段路

这一点，我们必须坦诚说明。

论文作者自己也明确提出，下一阶段需要继续开展：

规模化制造

系统性的临床前安全性研究

大型动物实验

以及进一步的疗效与安全性验证。

论文特别提到包括：

Beagle dogs

在内的大动物模型研究。

这意味着目前仍然属于：

Preclinical Research

临床前研究阶段。

所以今天不能把它写成：

❌ “纳米机器人已经可以治疗癌症。”

也不能写成：

❌ “癌症以后打一针就可以治好。”

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com

更严谨的表述是：

这项研究为主动趋化纳米药物递送提供了新的临床前证据，并为未来精准肿瘤治疗提供了一种值得进一步验证的技术路线。

十一、MLJC 的判断：真正的未来可能不是“机器人”

如果把“机器人”两个字去掉，我们会看到一个更深层的问题：

Can medicine become navigable?

药物能不能拥有方向？

过去：

药物被人体运输。

未来：

药物递送系统可能参与运输。

再往前：

药物递送系统可能感知环境。

更远的未来：

它甚至可能根据环境变化调整自己的运动、定位和释放行为。

于是形成：

JY HEALTHCARE GROUP SDN BHD (1185177-T)

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com

SENSE
感知
↓
NAVIGATE
导航
↓
TARGET
定位
↓
PENETRATE
穿透
↓
DELIVER
递送
↓
RESPOND
响应

这才是纳米机器人真正值得研究的长期方向。

JY HEALTHCARE GROUP SDN BHD (1185177-T)

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com



JY HEALTHCARE GROUP SDN BHD (1185177-T)

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com

十二、从中国科研到全球医疗产业

MLJC 认为，中国在这一领域值得国际社会持续观察。

原因并不只是“中国做出了一个纳米机器人”。

真正值得关注的是：

中国科研正在推动：

材料

→

纳米工程

→

生物医学

→

药物递送

→

精准治疗

之间更加紧密的融合。

JY HEALTHCARE GROUP SDN BHD (1185177-T)

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com

如果未来这些技术能够完成：

实验室验证
↓
动物安全性
↓
规模化制造
↓
监管评价
↓
人体临床试验
↓
临床有效性验证
↓
产业化

那么它才可能真正从：

Scientific Discovery

走向：

Medical Technology

最终走向：

Clinical Practice

JY HEALTHCARE GROUP SDN BHD (1185177-T)

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com

十三、MLJC | JY HCG 的长期观察

我们尤其关注的不是某一个“轰动数字”。

而是技术背后的产业链。

未来真正需要解决的问题包括：

01 | Safety

长期安全性如何？

02 | Biocompatibility

材料在人体内的生物相容性如何？

03 | Clearance

治疗完成以后，纳米材料如何代谢与清除？

04 | Manufacturing

能否实现稳定、可重复、符合 GMP 要求的规模化生产？

05 | Dosimetry / Dosing

如何准确控制治疗剂量？

06 | Target Specificity

如何避免正常组织非靶向累积？

07 | Regulatory

如何建立适用于纳米机器人产品的监管评价体系？

08 | Clinical Evidence

动物结果能否在人类临床试验中重复？

这八个问题，决定它最终能否从：

论文

走向：

医院。

十四、儒家式的医学观察

MLJC丨JY HCG 希望保持一种我们自己的态度：

见新而不惑，见成而不夸，见未成而不妄。

医学的进步值得欢欣。

但患者的生命，更值得敬畏。

所以我们既不会因为“纳米机器人”四个字而盲目追捧，也不会因为技术尚处于临床前阶段而轻视它的价值。

真正严肃的医疗观察，应当同时看到：

它已经证明了什么；

它尚未证明什么；

下一步必须证明什么。

这三件事缺一不可。

JY HEALTHCARE GROUP SDN BHD (1185177-T)

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com

十五、MLJC FINAL VIEW

这项研究目前还不能告诉我们：

“打一针就能治癌症。”

但它已经向科学界提出了一个值得认真研究的问题：

如果药物能够感知人体内部的化学环境，并借此改变自己的运动方向，癌症治疗的药物递送方式是否能够发生改变？

武汉理工大学官建国团队的研究给出了一个**临床前层面的积极答案**。

它不是终点。

甚至还不是临床应用的起点。

它更像是：

A NEW ENGINEERING POSSIBILITY

一种新的工程可能性。

从：

被动运输药物

走向：

主动寻找治疗路径。

从：

药物抵达哪里

走向：

JY HEALTHCARE GROUP SDN BHD (1185177-T)

Address :No. 14-2, Jalan 9/125D, Taman Desa Petaling, 57100 Kuala Lumpur.
Phone : +6012-6789137
Email : info@jy-holding.com

药物如何更有效地抵达应该去的地方。

这或许才是“纳米机器人治疗癌症”这一新闻背后，最值得国际医疗界认真阅读的内容。